165 related articles for article (PubMed ID: 22644297)
1. Chromosome instability and benefit from adjuvant anthracyclines in breast cancer.
Munro AF; Twelves C; Thomas JS; Cameron DA; Bartlett JM
Br J Cancer; 2012 Jun; 107(1):71-4. PubMed ID: 22644297
[TBL] [Abstract][Full Text] [Related]
2. A four gene signature predicts benefit from anthracyclines: evidence from the BR9601 and MA.5 clinical trials.
Spears M; Yousif F; Lyttle N; Boutros PC; Munro AF; Twelves C; Pritchard KI; Levine MN; Shepherd L; Bartlett JM
Oncotarget; 2015 Oct; 6(31):31693-701. PubMed ID: 26372731
[TBL] [Abstract][Full Text] [Related]
3. Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601).
Bartlett JM; Munro AF; Dunn JA; McConkey C; Jordan S; Twelves CJ; Cameron DA; Thomas J; Campbell FM; Rea DW; Provenzano E; Caldas C; Pharoah P; Hiller L; Earl H; Poole CJ
Lancet Oncol; 2010 Mar; 11(3):266-74. PubMed ID: 20079691
[TBL] [Abstract][Full Text] [Related]
4. Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial.
Pritchard KI; Munro A; O'Malley FP; Tu D; Li X; Levine MN; Shepherd L; Chia S; Bartlett JM
Breast Cancer Res Treat; 2012 Jan; 131(2):541-51. PubMed ID: 22042366
[TBL] [Abstract][Full Text] [Related]
5. Extreme chromosomal instability forecasts improved outcome in ER-negative breast cancer: a prospective validation cohort study from the TACT trial.
Jamal-Hanjani M; A'Hern R; Birkbak NJ; Gorman P; Grönroos E; Ngang S; Nicola P; Rahman L; Thanopoulou E; Kelly G; Ellis P; Barrett-Lee P; Johnston SR; Bliss J; Roylance R; Swanton C
Ann Oncol; 2015 Jul; 26(7):1340-6. PubMed ID: 26003169
[TBL] [Abstract][Full Text] [Related]
6. A four gene signature of chromosome instability (CIN4) predicts for benefit from taxanes in the NCIC-CTG MA21 clinical trial.
Spears M; Lyttle N; D'Costa A; Chen BE; Yao CQ; Boutros PC; Burnell M; Levine MN; O'Brien P; Shepherd L; Bartlett JM
Oncotarget; 2016 Aug; 7(31):49099-49106. PubMed ID: 27056899
[TBL] [Abstract][Full Text] [Related]
7. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial.
Bartlett JM; Munro A; Cameron DA; Thomas J; Prescott R; Twelves CJ
J Clin Oncol; 2008 Nov; 26(31):5027-35. PubMed ID: 18768436
[TBL] [Abstract][Full Text] [Related]
8. Correlation of MYC Gene and Protein Status With Breast Cancer Subtypes and Outcome of Patients Treated With Anthracycline-Based Adjuvant Chemotherapy. Pooled Analysis of 2 Hellenic Cooperative Group Phase III Trials.
Batistatou A; Kotoula V; Bobos M; Kouvatseas G; Zagouri F; Tsolaki E; Gogas H; Koutras A; Pentheroudakis G; Timotheadou E; Pervana S; Goussia A; Petraki K; Sotiropoulou M; Koletsa T; Razis E; Kosmidis P; Aravantinos G; Papadimitriou C; Pectasides D; Fountzilas G
Clin Breast Cancer; 2018 Feb; 18(1):53-62.e3. PubMed ID: 28870680
[TBL] [Abstract][Full Text] [Related]
9. Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Tibau A; López-Vilaró L; Pérez-Olabarria M; Vázquez T; Pons C; Gich I; Alonso C; Ojeda B; Ramón y Cajal T; Lerma E; Barnadas A; Escuin D
Neoplasia; 2014 Oct; 16(10):861-7. PubMed ID: 25379022
[TBL] [Abstract][Full Text] [Related]
10. Anthracycline Use for Early Stage Breast Cancer in the Modern Era: a Review.
Jasra S; Anampa J
Curr Treat Options Oncol; 2018 May; 19(6):30. PubMed ID: 29752560
[TBL] [Abstract][Full Text] [Related]
11. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.
Di Leo A; Desmedt C; Bartlett JM; Piette F; Ejlertsen B; Pritchard KI; Larsimont D; Poole C; Isola J; Earl H; Mouridsen H; O'Malley FP; Cardoso F; Tanner M; Munro A; Twelves CJ; Sotiriou C; Shepherd L; Cameron D; Piccart MJ; Buyse M;
Lancet Oncol; 2011 Nov; 12(12):1134-42. PubMed ID: 21917518
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of ANLN contributed to poor prognosis of anthracycline-based chemotherapy in breast cancer patients.
Wang Z; Chen J; Zhong MZ; Huang J; Hu YP; Feng DY; Zhou ZJ; Luo X; Liu ZQ; Jiang WZ; Zhou WB
Cancer Chemother Pharmacol; 2017 Mar; 79(3):535-543. PubMed ID: 28243684
[TBL] [Abstract][Full Text] [Related]
13. Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial.
Cheang MC; Voduc KD; Tu D; Jiang S; Leung S; Chia SK; Shepherd LE; Levine MN; Pritchard KI; Davies S; Stijleman IJ; Davis C; Ebbert MT; Parker JS; Ellis MJ; Bernard PS; Perou CM; Nielsen TO
Clin Cancer Res; 2012 Apr; 18(8):2402-12. PubMed ID: 22351696
[TBL] [Abstract][Full Text] [Related]
14. PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients.
Absmaier M; Napieralski R; Schuster T; Aubele M; Walch A; Magdolen V; Dorn J; Gross E; Harbeck N; Noske A; Kiechle M; Schmitt M
Int J Oncol; 2018 Mar; 52(3):755-767. PubMed ID: 29328369
[TBL] [Abstract][Full Text] [Related]
15. BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer.
Mori H; Kubo M; Nishimura R; Osako T; Arima N; Okumura Y; Okido M; Yamada M; Kai M; Kishimoto J; Miyazaki T; Oda Y; Otsuka T; Nakamura M
PLoS One; 2016; 11(12):e0167016. PubMed ID: 27977696
[TBL] [Abstract][Full Text] [Related]
16. The role of topoisomerase IIα in predicting sensitivity to anthracyclines in breast cancer patients: a meta-analysis of published literatures.
Du Y; Zhou Q; Yin W; Zhou L; Di G; Shen Z; Shao Z; Lu J
Breast Cancer Res Treat; 2011 Oct; 129(3):839-48. PubMed ID: 21809115
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant chemotherapy in early breast cancer.
Ejlertsen B
Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
[TBL] [Abstract][Full Text] [Related]
18. Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: a retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy.
Bozovic-Spasojevic I; Ameye L; Paesmans M; Larsimont D; Di Leo A; Dolci S; Piccart M; de Azambuja E; Loi S
Breast; 2014 Aug; 23(4):473-81. PubMed ID: 24768477
[TBL] [Abstract][Full Text] [Related]
19. Topoisomerase II α Gene alteration in Triple Negative Breast Cancer and Its Predictive Role for Anthracycline-Based Chemotherapy (Egyptian NCI Patients).
Eltohamy MI; Badawy OM; El kinaai N; Loay I; Nassar HR; Allam RM; Sakr MA
Asian Pac J Cancer Prev; 2018 Dec; 19(12):3581-3589. PubMed ID: 30583686
[TBL] [Abstract][Full Text] [Related]
20. Is anthracycline-based chemotherapy alone adequate for young women with estrogen receptor-positive breast cancer?
Papaldo P; Di Cosimo S; Ferretti G; Carlini P; Fabi A; Cecere F; Cognetti F
Breast; 2006 Apr; 15(2):269-72. PubMed ID: 16131469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
